Clinical Trials
6 trialsNCT07272499 2025-12-09
Orelabrutinib Plus Lisaftoclax and Rituximab in Untreated Mantle Cell Lymphoma With High-Risk Disease
Ruijin Hospital
Phase 2 Recruiting
NCT07206264 2025-10-03
ADAPT-MCL
Tianjin Medical University Cancer Institute and Hospital
Phase 2 Not yet recruiting
NCT07199296 2025-09-30
Orelabrutinib and Rituximab With Optional Autologous Hematopoietic Stem Cell Transplantation in MCL Treatment
Ruijin Hospital
Phase 2 Recruiting
NCT06656221 2024-11-19
A Prospective, Single-Center Study Evaluating the Efficacy and Safety of Glofitamab Combined With Orelabrutinib and Bortezomib in Patients With High-Risk Mantle Cell Lymphoma
Ruijin Hospital
Phase 2 Not yet recruiting
NCT05978739 2023-10-25
Evaluating Different Doses of Orelabrutinib in MCL
InnoCare Pharma Inc.
Phase 2 Unknown
NCT05076097 2021-11-11
A Study of OLR in First-line Treatment of Mantle Cell Lymphoma
Tianjin Medical University Cancer Institute and Hospital
Phase 2 Unknown